Ligand Pharmaceuticals LGND Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $51.72M-13.3% | $59.67M-48.3% | $115.46M+142% | $47.63M+5.1% | $45.33M+5.9% | ||
| $2.15M-38.8% | $3.51M-83.3% | $21.02M+220% | $6.57M-86.9% | $50.09M+1,032% | ||
| $20.84M-16.7% | $25.03M-12.0% | $28.45M+41.0% | $20.18M+7.3% | $18.8M-26.6% | ||
| $34.35M-25.0% | $45.82M-24.3% | $60.53M+54.5% | $39.18M-52.0% | $81.55M+55.5% | ||
| $17.37M+25.5% | $13.84M-74.8% | $54.93M+551% | $8.44M+123% | -$36.22M-276% | ||
| 33.6%+10.4pp | 23.2%-24.4pp | 47.6%+29.8pp | 17.7%+97.6pp | -79.9%-57.4pp | ||
| $1.75M-2.1% | $1.79M+96.2% | $910K-21.1% | $1.15M+33.0% | $867K-1.8% | ||
| $6.66M+4.1% | $6.39M+65.0% | $3.87M+139% | $1.62M-8.5% | $1.77M-8.3% | ||
| -$41.63M-197% | $42.94M-50.2% | $86.21M+3,002% | $2.78M+120% | -$13.96M— | ||
| $3.87M+6.6% | $3.63M-53.4% | $7.8M+730% | $939K+108% | -$12.37M+87.5% | ||
| -$24.26M-143% | $56.78M-59.8% | $141.14M+1,158% | $11.22M+122% | -$50.18M— | ||
| -$10.91M-191% | $12M-49.7% | $23.86M+274% | $6.38M+182% | -$7.73M— | ||
| -$13.35M-130% | $44.78M-61.8% | $117.27M+2,319% | $4.85M+111% | -$42.45M-36.6% | ||
| -25.8%-101pp | 75.1%-26.5pp | 101.6%+91.4pp | 10.2%+104pp | -93.6%-21.0pp | ||
| -$0.67-131% | $2.18-61.6% | $5.68+2,267% | $0.24+111% | -$2.21-31.5% | ||
| -$0.67-129% | $2.33-61.1% | $5.99+2,296% | $0.25+111% | -$2.21-28.5% | ||
| 19.9M-2.0% | 20.3M-1.6% | 20.6M+3.5% | 19.9M+3.8% | 19.2M+4.9% | ||
| 19.9M+2.8% | 19.3M-1.2% | 19.6M+1.3% | 19.3M+0.7% | 19.2M+4.9% | ||
| $8.1M0.0% | $8.1M0.0% | $8.1M-1.9% | $8.26M0.0% | $8.26M0.0% | ||
| $3.27M+9.4% | $2.99M-21.3% | $3.8M+30.8% | $2.91M-40.0% | $4.85M+70.9% | ||
| $0— | $0-100% | $833K+165% | -$1.28M-388% | $443K+106% | ||
| -$49.23M-433% | $14.78M-80.5% | $75.89M— | $0— | $0— | ||
| -$1.18M— | —— | -$443K-132% | $1.37M+155% | -$2.5M+62.7% | ||
| $51.72M-13.3% | $59.67M-48.3% | $115.46M+142% | $47.63M+5.1% | $45.33M+5.9% | ||
| $17.37M+25.5% | $13.84M-74.8% | $54.93M+551% | $8.44M+123% | -$36.22M-276% | ||
| $25.58M+16.0% | $22.06M-65.1% | $63.2M+273% | $16.97M+162% | -$27.45M-2,617% | ||
| $25.58M+16.0% | $22.06M-65.1% | $63.2M+273% | $16.97M+162% | -$27.45M-2,617% | ||
| 49.5%+12.5pp | 37%-17.8pp | 54.7%+19.1pp | 35.6%+96.2pp | -60.5%-58.2pp | ||
| $17.37M+25.5% | $13.84M-74.8% | $54.93M+551% | $8.44M+123% | -$36.22M-276% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ligand Pharmaceuticals's profit margins?
- Gross margin is 91.9% and operating margin is 34.5%, with a 55.9% net margin.
- Where does Ligand Pharmaceuticals's income statement data come from?
- Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.